Extended Data Fig. 7: STM2457 treatment is efficacious and targeted in primary murine AML.

a, Percentage of YFP⁺ MLL-AF9/Flt3^Itd/+ cells in the bone marrow of mice treated with vehicle or 30 mg/kg STM2457 (mean ± s.d., n = 4). b, Spleen weight of MLL-AF9/Flt3^Itd/+ murine AML models following treatment with vehicle or 30 mg/kg STM2457 (mean ± s.d., n = 4). c, Western blot showing SP1, BRD4, HNRNPL, BCL2, METTL3 and ACTIN protein levels in murine AML (MLL-AF9/Flt3^Itd/+) models treated with either vehicle or 30 mg/kg STM2457 (n = 4). d, RNA-mass spectrometry quantification of m⁶A levels on poly-A⁺-enriched RNA in vivo from AML murine models (MLL-AF9/Flt3^Itd/+) treated with vehicle, 30 mg/kg STM2457 or 50 mg/kg STM2457 (mean ± s.d., n = 4). e, Percentage of CD93⁺ cells in the bone marrow of MLL-AF9/Flt3^Itd/+ murine models following treatment with either vehicle or 30 mg/kg STM2457 (mean ± s.d., n = 5). f, Percentage of L-GMP cells in the bone marrow of MLL-AF9/Flt3^Itd/+ murine models following treatment with either vehicle or 30 mg/kg STM2457 (mean ± s.d., n = 5). g, CD48 levels of L-GMP cells in the bone marrow of MLL-AF9/Flt3^Itd/+ murine models following treatment with either vehicle or 30 mg/kg STM2457 (mean ± s.d., n = 5). h. Kaplan–Meier survival after re-transplantation of cells isolated from primary transplanted animals with MLL-AF9/Flt3^Itd/+ treated and treated with either vehicle or 30 mg/kg STM2457 (n = 5). i, Percentage of YFP⁺ cells in the peripheral blood 12 days after re-transplantation with MLL-AF9/Flt3^Itd/+ (mean ± s.d., n = 5). D, day; BM, bone marrow; PBC, peripheral blood count; n.s. not significant; two-tailed Student’s t-test; Log-rank (Mantel–Cox) test was used for survival comparisons.

Source data